US › Healthcare

Inovio Pharmaceuticals Inc (INO)

US · Healthcare · Biotechnology

$0.66-4.84%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-19.7M
Profit YoY
+0.1%
EPS
$-0.31
EPS estimate
$-0.33

EPS came in at -0.31 against a street estimate of -0.33 — a beat of 6.1%.

Key statistics

Market cap
$55.7M
Forward P/E
16.6
P/B
9.18
Book value
$0.09
EPS (TTM)
$-1.58
52-week high
$2.98
52-week low
$0.56
50-day MA
$1.13
200-day MA
$1.58
Beta
1.51

Analyst view

Analysts rate Inovio Pharmaceuticals Inc a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $3.43.

Shareholding

Insiders
0.42%
Institutions
47.30%

Largest institutional holders

FundStake
FMR Inc11.35%
Vanguard Group Inc4.03%
HHG PLC4.02%
Vanguard Capital Management, LLC3.53%
Boxer Capital Management, LLC2.88%
D. E. Shaw & Co LP2.69%
ADAR1 Capital Management LLC1.79%
Millennium Management LLC1.71%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Inovio Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.